title: Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome.
abstract: OBJECTIVE
  Exogenous surfactant has been proposed as adjunctive therapy for acute respiratory distress syndrome (ARDS), but it is inactivated by different factors present in the alveolar space. We hypothesized that co-administration of LASSBio596, a molecule with significant anti-inflammatory properties, and exogenous surfactant could reduce lung inflammation, thus enabling the surfactant to reduce edema and improve lung function, in experimental ARDS.
  
  
  METHODS
  ARDS was induced by cecal ligation and puncture surgery in BALB/c mice. A sham-operated group was used as control (CTRL). After surgery (6 hours), CTRL and ARDS animals were assigned to receive: (1) sterile saline solution; (2) LASSBio596; (3) exogenous surfactant or (4) LASSBio596 plus exogenous surfactant (n = 22/group).
  
  
  RESULTS
  Regardless of exogenous surfactant administration, LASSBio596 improved survival rate and reduced collagen fiber content, total number of cells and neutrophils in PLF and blood, cell apoptosis, protein content in BALF, and urea and creatinine levels. LASSBio596 plus surfactant yielded all of the aforementioned beneficial effects, as well as increased BALF lipid content and reduced surface tension.
  
  
  CONCLUSIONS
  LASSBio596 exhibited major anti-inflammatory and anti-fibrogenic effects in experimental sepsis-induced ARDS. Its association with surfactant may provide further advantages, potentially by reducing surface tension.
authors.affiliation: Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Johnatas Dutra
authors.initials: JD
authors.lastname: Silva
authors.forename: Gisele Pena
authors.initials: GP
authors.lastname: de Oliveira
authors.forename: Cynthia dos Santos
authors.initials: Cdos S
authors.lastname: Samary
authors.forename: Carla Cristina
authors.initials: CC
authors.lastname: Araujo
authors.forename: Gisele de Araujo
authors.initials: Gde A
authors.lastname: Padilha
authors.forename: Fernando
authors.initials: F
authors.lastname: Costa e Silva Filho
authors.forename: Rosilane Taveira
authors.initials: RT
authors.lastname: da Silva
authors.forename: Marcelo
authors.initials: M
authors.lastname: Einicker-Lamas
authors.forename: Marcelo Marcos
authors.initials: MM
authors.lastname: Morales
authors.forename: Vera Luiza
authors.initials: VL
authors.lastname: Capelozzi
authors.forename: Vanessa Martins
authors.initials: VM
authors.lastname: da Silva
authors.forename: Lídia Moreira
authors.initials: LM
authors.lastname: Lima
authors.forename: Eliezer Jesus
authors.initials: EJ
authors.lastname: Barreiro
authors.forename: Bruno Lourenço
authors.initials: BL
authors.lastname: Diaz
authors.forename: Paolo
authors.initials: P
authors.lastname: Pelosi
authors.forename: Pedro Leme
authors.initials: PL
authors.lastname: Silva
authors.forename: Cristiane Souza Nascimento Baez
authors.initials: CS
authors.lastname: Garcia
authors.forename: Patricia Rieken Macedo
authors.initials: PR
authors.lastname: Rocco
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001688:Biological Products / Q000627:therapeutic use*; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008297:Male; D008807:Mice, Inbred BALB C; D010795:Phthalic Acids / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D013449:Sulfonamides / Q000627:therapeutic use*; D013500:Surface Tension / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D001688:Biological Products; C514420:LASSBIO596; D010795:Phthalic Acids; D011663:Pulmonary Surfactants; D013449:Sulfonamides; C072197:beractant